Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

References

• AnagnostouALeeESKessimianN1990Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cellsProc Natl Acad Sci U S A875978822165612
   PubMed Web of Science ®Google Scholar
• BailonPPahlkeWBrandtM2003CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia:a new agent with an innovative mechanism of action [abstract]Nephrol Dial Transplant166Suppl 4
   Google Scholar
• BarrePReichelHSuranyiMG2004Efficacy of once-weekly epoetin alfaClin Nephrol62440815630903
   PubMed Web of Science ®Google Scholar
• BesarabABansalVFishbaneS2004Intravenous CERA (Continuous Erythropoiesis Receptor Activator) administered once weekly or once every 2 weeks maintains haemoglobin levels in haemodialysis patients with chronic renal anemia [abstract]. Abstract Book of the XLI Congress of the ERA-EDTA 230 (Abstract M047).
   Google Scholar
• BrunkhorstRBommerJBraunJ2004Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patientsNephrol Dial Transplant1912243014993489
   PubMed Web of Science ®Google Scholar
• de FranciscoALSulowiczWDoughertyFC2003Subcutaneous CERA (Continuous Erythropoiesis Receptor Activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia:an exploratory multiple dose study [abstract]J Am Soc Nephrol1427A–28A(Abstract SA-FC124).
   Google Scholar
• DmoszynskaAKloczkoJRokickaM2004CERA (Continuous Erythropoiesis Receptor Activator) in patients with multiple myeloma: an exploratory phase I-II dose escalation study [abstract]J Clin Oncol22Suppl 514S(Abstract 6552).
   Google Scholar
• DoughertyFCBeyerU2005aNo changes in blood pressure in dialysis patients after 12 months of treatment with i.v. or s.c. CERA (Continuous Erythropoietin Receptor Activator)[abstract]Nephrology10Suppl.(A313):Abstract W-PO40131.
   Google Scholar
• DoughertyFCBeyerU2005bSafety and tolerability profile of Continuous Erythropoietin receptor Activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis [abstract]Nephrology10A313Abstract W-PO40130
   Google Scholar
• DoughertyFCLeypoldtJKCheungAK2003No effect of hamodialysis or hemofiltration on concentrations of CERA (Continuous Erythropoiesis Receptor Activator): In Vitro Study Results [abstract]J Am Soc Nephrol14770ASU-PO1065
   Google Scholar
• DoughertyFCReignerBJordanP2004CERA (Continuous Erythropoiesis Receptor Activator):dose-response, pharmacokinetics and tolerability in phase 1 multiple ascending dose studies [abstract]J Clin Oncol22Suppl 1514S(Abstract 6692).
   Google Scholar
• EschbachJWEgrieJCDowningMR1987Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trialN Engl J Med3167383537801
   PubMed Web of Science ®Google Scholar
• FauldsDSorkinEM1989Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesisDrugs38863992693045
   PubMed Web of Science ®Google Scholar
• FishbaneSPannierALiogierX2005Pharmacokinetic (PK) properties of subcutaneous (s.c.) CERA (Continuous Erythropoietin Receptor Activator) are unaffected by administration site [abstract]J Am Soc Nephrol16SA-PO942
   Google Scholar
• FishbaneSTareNPillJ2003Preclinical pharmacodynamics and pharmacokinetics of CERA (Continuous Erythropoeitin Receptor Activator), an innovative erythropoietic agent for anemia management in patients with kidney disease [abstract]J Am Soc Nephrol14Abstract SA-FC 123
   Web of Science ®Google Scholar
• HalstensonCEMacresMKatzA1991Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin betaClin Pharmacol Ther50702121752115
   PubMed Web of Science ®Google Scholar
• HaselbeckABailonPPahlkeW2002The discovery and characterization of CERA, an innovative agent for the treatment of anemia [abstract]Blood100Abstract 857
   Web of Science ®Google Scholar
• JacobsKShoemakerCRudersdorfR1985Isolation and characterization of genomic and cDNA clones of human erythropoietinNature3136005806103838366
   PubMed Web of Science ®Google Scholar
• JadoulMVanrenterghemYForetM2004Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patientsNephrol Dial Transplant1989890315031347
   PubMed Web of Science ®Google Scholar
• KawakamiMSekiguchiMSatoK2001Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemiaJ Biol Chem276394697511504731
   PubMed Web of Science ®Google Scholar
• LingBWalczykMAgarwalA2005Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney diseaseClin Nephrol633273415909591
   PubMed Web of Science ®Google Scholar
• LocatelliFAljamaPBaranyP2004Revised European best practice guidelines for the management of anaemia in patients with chronic renal failureNephrol Dial Transplant19Suppl 2ii14715206425
   PubMedGoogle Scholar
• LocatelliFCanaudBGiacardyF2003Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)Nephrol Dial Transplant18362912543893
   PubMed Web of Science ®Google Scholar
• LocatelliFConteFMarcelliD1998The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity–the experience of the Lombardy Dialysis RegistryNephrol Dial Transplant13164249681705
   PubMed Web of Science ®Google Scholar
• LocatelliFVillaG2004CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks [abstract]J Am Soc Nephrol15SU-PO051
   Google Scholar
• MaJZEbbenJXiaH1999Hematocrit level and associated mortality in hemodialysis patientsJ Am Soc Nephrol10610910073612
   PubMed Web of Science ®Google Scholar
• MacdougallICBailonPTareN2003CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life [abstract]J Am Soc Nephrol14Abstract SU-PO1063
   Web of Science ®Google Scholar
• MacdougallICGraySJElstonO1999Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patientsJ Am Soc Nephrol102392510541299
   PubMed Web of Science ®Google Scholar
• MacdougallICMatchamJGraySJ2003Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysisNephrol Dial Transplant185768112584282
   PubMed Web of Science ®Google Scholar
• MacdougallICRobsonROpatrnaS2005Pharmacologic Profile of CERA (Continuous Erythropoietin Receptor Activator) in chronic kidney disease (CKD) patients (pts) following intravenous (i.v.) and subcutaneous (s.c.) administration [abstract]J Am Soc Nephrol16SA-PO926
   Google Scholar
• MadoreFLowrieEGBrugnaraC1997Anemia in hemodialysis patients:variables affecting this outcome predictorJ Am Soc Nephrol8192199402095
   PubMed Web of Science ®Google Scholar
• MiyakeTKungCKGoldwasserE1977Purification of human erythropoietinJ Biol Chem25255586418467
   PubMed Web of Science ®Google Scholar
• NissensonARSwanSKLindbergJS2002Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patientsAm J Kidney Dis40110812087568
   PubMed Web of Science ®Google Scholar
• ParfreyPSFoleyRNWittreichBH2005Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart diseaseJ Am Soc Nephrol162180915901766
   PubMed Web of Science ®Google Scholar
• PollockCMcMahonL2005The CARI Guidelines: HaemoglobinNephrology10S4S108S11516221113
   PubMed Web of Science ®Google Scholar
• ProvenzanoRBesarabAMacdougallIC2004CERA (Continuous Erythropoietin Receptor Activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis [abstract]J Am Soc Nephrol15Abstract SU-PO056
   Google Scholar
• RaynerHCPisoniRLBommerJ2004Mortality and hospitalization in haemodialysis patients in five European countries:results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrol Dial Transplant191082014671046
   PubMed Web of Science ®Google Scholar
• ReignerBJordanPPannierA2003Phase 1 studies of the new erythropoietic agent, CERA (continuous erythropoiesis receptor cativator):demonstration of a dose-dependent response [abstract]Nephrol Dial Transplant18Suppl 4167(Abstract M527)
   Google Scholar
• RibattiDPrestaMVaccaA1999Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivoBlood9326273610194442
   PubMed Web of Science ®Google Scholar
• RibattiDVaccaARoccaroA M2003Erythropoietin as an angiogenic factorEur J Clin Invest33891614511361
   PubMed Web of Science ®Google Scholar
• ScottSD2002Dose conversion from recombinant human erythropoietin to darbepoetin alfa:recommendations from clinical studiesPharmacotherapy22160S165S12222586
   PubMed Web of Science ®Google Scholar
• SekiguchiNInoguchiTKobayashiK2004Effect of erythropoietin on endothelial cell apoptosis induced by high glucoseDiabetes Res Clin Pract66Suppl 1S103715563957
   PubMed Web of Science ®Google Scholar
• TheodoridisMPassadakisPKrikiP2005Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patientsPerit Dial Int25564916411523
   PubMed Web of Science ®Google Scholar
• XiaHEbbenJMaJZ1999Hematocrit levels and hospitalization risks in hemodialysis patientsJ Am Soc Nephrol1013091610361870
   PubMed Web of Science ®Google Scholar
• YamajiROkadaTMoriyaM1996Brain capillary endothelial cells express two forms of erythropoietin receptor mRNAEur J Biochem2394945008706759
   PubMedGoogle Scholar